Biotech company Biogen (BIIB) has faced substantial developments recently. Despite experiencing a price target reduction across various firms such as Mizuho and JP Morgan, the company still maintains appealing rankings. Its investigational therapy, BIIB080, received FDA Fast Track Designation for Alzheimer's Treatment while their epilepsy drug caused them to lower their profit outlook. Axa S.A. increased its BIIB holdings while Brown Advisory Inc. bought shares of the company. However, Q1's earnings missed expectations.
Lido Advisors acquired a large share, 39,910, of Biogen. Biogen displayed robust Q1 performance, surpassing their revenue expectations while their profit outlook was reduced following the deal for their epilepsy drug. Positively, the firm's stock still soared by 5.7% with expectations of further upside. Results revealed a significant drop in their Q1 2025 adjusted profit despite higher revenues. Their Alzheimer's drug received FDA Fast Track designation, despite an US$8M settlement. Subsequently, regulatory updates in the EU for this drug caused a decrease in their stock.
Enrollment completed for a Parkinson's treatment study. Finally, HC Wainwright & Co. lowered their price target for Biogen, while their bold move to transform Kendall Square Research Hub into a 580,000 sq ft innovation powerhouse brought positive attention.
Biogen BIIB News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 10 May 2025 09:43:52 GMT - Rating -1 - Innovation 7 - Information 4 - Rumor 1
